Biocon Crosses $1bn Threshold In Biosimilars Revenue
Wider Results Met With Analyst Uncertainty
The Indian business crossed a major threshold as its biosimilars division earned over $1bn in revenue in the 2024 fiscal year, while also facing analyst skepticism over the performance of its other businesses.
